Current Opinion in Investigational Drugs 2001-03-01

Donitriptan (Pierre Fabre).

M Dukat

Index: Curr. Opin. Investig. Drugs 2(3) , 415-8, (2001)

Full Text: HTML

Abstract

Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development [396027]. This compound has an increased potency and, importantly, markedly higher intrinsic activity in comparison to the well described tryptamine derivatives, naratriptan, zolmitriptan and sumatriptan [295769].

Related Compounds

Related Articles:

Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.

2006-09-01

[Br. J. Pharmacol. 149(1) , 82-91, (2006)]

Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs.

2002-02-01

[Cephalalgia 22(1) , 37-47, (2002)]

Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries.

2002-05-17

[Eur. J. Pharmacol. 443(1-3) , 125-32, (2002)]

An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.

2001-05-01

[Pain 92(1-2) , 101-6, (2001)]

F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.

1999-07-01

[J. Pharmacol. Exp. Ther. 290(1) , 83-95, (1999)]

More Articles...